Members of the scientific committee

  • Christian Moretti

    Chairman

    • Board of Directors
    • Executive Commitee

    Christian Moretti is a graduate of Ecole des Hautes Etudes Commerciales (HEC - 1969) with an MBA from Columbia Business School (1970) in New York.

    He started his career with Banque Paribas from 1970 to 1980 where he was Director within the investment arm, overseeing 250 industrial investments and later Director of the International Corporate Finance division with Banque Privée de Gestion Financière (1980-82).

    From 1973 to 1983, Christian was also a Full Professor at Ecole Supérieure de Commerce de Paris (SupdeCo Paris) teaching Finance, Investment, Banking and Stock Markets.

    In 1982, Christian and his best friend, Henri Blanchet, founded the Dynaction Group which was an early star of the French private equity scene. During these golden years, Dynaction acquired many companies amongst which PCAS and began a recentering of the conglomerate’s activities around Healthcare.

    The premature passing away of Henri in 1995 led to a further restructuration of the group culminating with the merger with PCAS in 2013. Christian remained Chairman of the Board(s). He is Chairman of the board of Quantel and sits on the Supervisory Board of Rubis.

    Christian is originally from Nice and is a keen tennis and golf player.

  • Philippe Delwasse

    Vice Chairman

    • Board of Directors
    • Executive Commitee

    A graduate of France’s Ecole Polytechnique, Philippe Delwasse started his career at “Compagnie de Pont-à-Mousson” (Saint Gobain).

    Over the next 30 years, he then held numerous management functions in the Paribas Group, first in the Industrial Affairs of the Bank, then as the Manager and General Secretary of “Nord Est”, a diversified industrial holding managing a turnover of over a billion euros.

    He joined PCAS in 2006 as a Managing Director, and is PCAS’s Vice President since 2011.

  • Vincent Touraille

    Chief Executive Officer

    • Executive Commitee
    • Scientific Commitee

    Mr. Vincent Touraille received his undergraduate degree from École Nationale Supérieure de Chimie de Paris in 1986 and from ESSEC Business School in 1989.

    He worked 10 years within Shell Group in different positions and joined PCAs in 1998 to manage Specialty Chemicals Business unit.

    Vincent Touraille served as General Manager of Pharmaceutical Activities of PCAS in 2004, then Chief Operating Officer of PCAS and Chief Executive Officer from March 2011.

    He is currently member of the Board of UIC Union des Industry Chimiques (French part of CEFIC), President of SICOS (French Fine Chemical Society) and board member of ESCOM and ENSCP.

  • Pierre Schreiner

    Chief Operating Officer

    • Executive Commitee

    Pierre Schreiner is Graduate of Ecole des Arts & Métiers (ENSAM) (1986).

    He built a 25 years experience in Automotive Industry in Saint-Gobain, Valeo and Visteon as Industrial Director and General Manager in several countries and international environment. Having joined Tata Steel, he brought that experience in a different industry market.

    Since May 2014 as COO of PCAS, he provides new ways of industry management to the company.

  • Éric Moissenot

    Senior Vice President of Finance & Administration

    • Executive Commitee

    Eric Moissenot is a Graduate of EM Lyon Business School (1987) and Qualified as a French “Commissaire aux Comptes” (equivalent of a chartered accountant).

    Before joining PCAS in October 2004 as CFO, Eric Moissenot worked as a senior manager for PricewaterhouseCoopers in the Audit Department. He was in charge of the audit of different firms in the industrial and services sectors.

    And currently he is Senior Vice President, Finance & Administration of PCAS Group.

  • Gérard Guillamot

    Head of Research & Development

    • Executive Commitee
    • Scientific Commitee

    Gerard Guillamot has a PhD in synthetic organic chemistry (1982) and started his career by University-Industry collaboration with PCAS before joining Merrell Dow Pharmaceuticals as a research engineer in 1984. In 1993, after almost 10 years dealing with the scale-up of N.C.E. (New Chemical Entity) he focused his career on Generic A.P.I. development for Schwarz Pharma. In 1998, he became R&D Manager and moved to PCAS Headquarters in Longjumeau. Since 1999, he acted as PCAS R&D Director in charge of the Labs, Pilots and Analytical development.

Contacts: